Animal · preclinical2026
Pharmacokinetic and pharmacodynamic properties of cannabigerol in male mice
Mabou Tagne et al. · The Journal of Pharmacology and Experimental Therapeutics
anxietypharmacokineticsbrainpreclinical
Research Library
Every verified study.
All 21 PubMed-verified publications behind CBG Atlas — filter by evidence tier, compound, and year; sort by recency or evidence strength. Every entry traces to its DOI and PubMed record.
The evidence
Browse the verified registry.
Filter and sort the full set. A study appearing here means it was verified against PubMed and graded by study type — not that it establishes a benefit.
Evidence
CompoundYears
Showing 21 of 21 studies
Human RCT2024
Acute effects of cannabigerol on anxiety, stress, and mood: a double-blind, placebo-controlled, crossover, field trial
Cuttler et al. · Scientific Reports
anxietystresshuman-evidencedosing
Animal · preclinical2023
Cannabigerol modulates α-adrenoceptor and 5-HT1A receptor-mediated electrophysiological effects on dorsal raphe nucleus and locus coeruleus neurons and anxiety behavior in rat
Mendiguren et al. · Frontiers in Pharmacology
anxiety-mechanism5-HT1Aalpha2-adrenoceptorbrain
Animal · preclinical2022
The cannabis constituent cannabigerol does not disrupt fear memory processes or stress-induced anxiety in mice
Zhou et al. · Cannabis and Cannabinoid Research
anxietyfear-memorynull-resultbrain
Review2021
The Pharmacological Case for Cannabigerol
Nachnani et al. · Journal of Pharmacology and Experimental Therapeutics
reviewreceptor-pharmacologyCBGtherapeutic-potential
Animal · preclinical2020
Uncovering the Hidden Antibiotic Potential of Cannabis
Farha et al. · ACS Infectious Diseases
antibacterialMRSAmembrane activitybiofilm
In vitro2018
In Vitro Model of Neuroinflammation: Efficacy of Cannabigerol, a Non-Psychoactive Cannabinoid
Gugliandolo et al. · International Journal of Molecular Sciences
neuroinflammationoxidative stressneuroprotectionin-vitro
Biochemistry2018
Elucidation of structure-function relationship of THCA and CBDA synthase from Cannabis sativa L.
Zirpel et al. · Journal of Biotechnology
biosynthesisenzymeCBCA
Animal · preclinical2016
Cannabigerol is a novel, well-tolerated appetite stimulant in pre-satiated rats
Brierley et al. · Psychopharmacology
appetitehyperphagiatolerabilitydigestive
Biochemistry2016
Decarboxylation study of acidic cannabinoids: a novel approach using ultra-high-performance supercritical fluid chromatography/photodiode array-mass spectrometry
Wang et al. · Cannabis and Cannabinoid Research
decarboxylationchemistrymanufacturing
Animal · preclinical2015
Neuroprotective properties of cannabigerol in Huntington's disease: studies in R6/2 mice and 3-nitropropionate-lesioned mice
Valdeolivas et al. · Neurotherapeutics
neuroprotectionHuntingtonbrainantioxidant
In vitro2015
Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor
Laprairie et al. · British Journal of Pharmacology
receptor-pharmacologyCB1comparisonCBD
Animal · preclinical2014
Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid
Borrelli et al. · Carcinogenesis
oncology-preclinicalcolonTRPM8digestive
Animal · preclinical2013
Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease
Borrelli et al. · Biochemical Pharmacology
anti-inflammatoryIBDdigestive
In vitro2011
Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes
De Petrocellis et al. · British Journal of Pharmacology
receptor-pharmacologyTRP-channelsTRPM8TRPV1
In vitro2010
Evidence that the plant cannabinoid cannabigerol is a highly potent alpha2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist
Cascio et al. · British Journal of Pharmacology
receptor-pharmacologyalpha2-adrenoceptor5-HT1ACB1
In vitro2008
Antibacterial cannabinoids from Cannabis sativa: a structure-activity study
Appendino et al. · Journal of Natural Products
antibacterialMRSAstructure-activity
Review2008
The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin
Pertwee et al. · British Journal of Pharmacology
receptor-pharmacologycomparisonTHCCBD
In vitro2005
Agonistic properties of cannabidiol at 5-HT1a receptors
Russo et al. · Neurochemical Research
receptor-pharmacology5-HT1AcomparisonCBD
Biochemistry2004
The gene controlling marijuana psychoactivity: molecular cloning and heterologous expression of Delta1-tetrahydrocannabinolic acid synthase from Cannabis sativa L.
Sirikantaramas et al. · Journal of Biological Chemistry
biosynthesisTHCA-synthaseenzyme
Biochemistry1996
Purification and characterization of cannabidiolic-acid synthase from Cannabis sativa L.
Taura et al. · Journal of Biological Chemistry
biosynthesisCBDA-synthaseenzyme
Figure M · coverage
A monograph for every compound
Open data
Download the registry.
The exact gated snapshot this page renders, in two forms — a typeset PDF to read and cite, and the machine-readable JSON to diff and check against the hash below. Both are generated from the same gated export, so they cannot disagree. Published by the multi-gate publish — the same artifacts the site, the knowledge graph, and Atlas read.
PDF · JSON
Evidence registry — full export
Every verified study with its evidence tier, first author, year, journal, DOI, PubMed record, topics, and per-study provenance hash. The PDF groups them by study design, strongest first, and carries the registry hash on every page.
PDF · JSON
Gap-map — the coverage map
Every tracked condition with its evidence status, its grade where one exists, and what is missing before that grade could move. Conditions with no primary evidence are in the file, not hidden from it. Read the gap-map.
Licence & provenance
Licensed CC BY-NC-SA 4.0 — attribute as: “CBG Atlas. Funded by Peregrine Biopharma, which holds no editorial authority.”. All four files are published by the multi-gate publish; the PDFs are typeset from the same gated exports as the JSON and add nothing to them. The evidence export carries the registry hash 154671f50c4acbb13f602b479f4fddeb6e455779db35c7e643b7a595e2173e3a (SHA-256, generated 2026-08-09), so you can prove exactly which snapshot you hold; the gap-map is a projection of that same gated registry and states its own build date in the file.
What this is and is not. It is our curated set of PubMed-verified, non-retracted primary sources — the registry every graded claim on this site is drawn from. It is not a systematic review and not a complete census of the literature: absence from this file is not evidence of absence, and nothing in it establishes clinical benefit in humans.